Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Core Insights - Foghorn Therapeutics is advancing FHD-909 (LY4050784), a first-in-class selective SMARCA2 inhibitor, in an ongoing Phase 1 trial targeting SMARCA4 mutated cancers, primarily focusing on non-small cell lung cancer (NSCLC) [1][2] - New preclinical data will be presented at the 2025 AACR Annual Meeting, showcasing the potential of FHD-909 in combination with chemotherapy, pembrolizumab, and KRAS inhibitors [1][2] - The company is also presenting preclinical data on its Selective CBP and EP300 degrader programs, which have demonstrated strong anti-tumor activities [2] FHD-909 Details - FHD-909 is an allosteric, orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 over SMARCA4, crucial for the BAF complex's function [6] - Preclinical studies indicate that tumors with SMARCA4 mutations depend on SMARCA2 for their BAF function, highlighting the therapeutic potential of FHD-909 [6] Presentation Information - An oral presentation titled "LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors" will take place on April 28, 2025 [3] - Poster presentations will cover the Phase 1 trial design for FHD-909 and preclinical data for the Selective CBP and EP300 degrader programs [4][5] Company Overview - Foghorn Therapeutics is focused on developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system [7] - The company utilizes its Gene Traffic Control platform to identify and validate potential drug targets, with multiple oncology product candidates in development [7]